LARISSA consortium reaches milestone: Novel Rift Valley fever vaccine dosed in Phase I human trial

The first healthy volunteer was dosed with hRVFV-4s, a novel live-attenuated Rift Valley fever vaccine. A clinical trial, run by the LARISSA[1] consortium and which started this week, will assess...
Read More

CEPI awards contract worth up to US$12.5 million to consortium led by Wageningen Bioveterinary Research to develop a human vaccine against Rift Valley fever

Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s...
Read More